DiaSorin this week reported revenues of 685.4 million euros ($699.9 million) for the first half of 2022, an increase of 33% year-over-year.
Revenues were driven in part by sales of products from Luminex, acquired last July for $1.8 billion.
The Saluggia, Italy-based diagnostic testing company also saw gains its sales of its immunodiagnostic and molecular diagnostic products, but its revenues were partly offset by a decline in COVID-related sales.
Without including revenues from COVID products, immunodiagnostics revenues in the first half of the year were 332.6 million euros, up 10% from 302.4 million euros in the prior-year period. These revenues were mainly due to a "solid performance" from latent tuberculosis, infectious disease, and gastrointestinal panel tests, the firm said.
Ex-COVID molecular diagnostics revenues were 96.7 million euros, up almost 171% from 35.7 million euros in the prior-year period.
Luminex licensed technologies revenues were 106.4 million euros compared to no recorded revenues in the prior half-year, and COVID-19 revenues were 149.8 million euros, down 15.5% compared to 177.3 million euros in the prior-year period.
For the first half of 2022, DiaSorin posted a net profit of 140.8 million euros compared to 150 million euros in the prior half-year.
For full-year 2022, DiaSorin anticipates 2% year-over-year revenue growth and 200 million euros in COVID-related revenues, with about a 24% rise in revenues unrelated to COVID testing.
